Molecular genetics and metabolismDec 14, 2025

Using mRNA to Treat Inherited Metabolic Diseases

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 19, 2026

Abstract

Initial phase I/II clinical trials and n = 1 cases in liver-dominant inherited metabolic diseases (IMDs) have shown encouraging results for mRNA-based therapies delivered by lipid nanoparticles.

Inherited metabolic diseases (IMDs) are caused by enzymatic deficiencies that disrupt essential biochemical pathways.
Current treatments for IMDs are largely supportive and do not target the underlying causes of these disorders.
Messenger RNA (mRNA) can enable temporary and programmable protein expression in targeted tissues.
Lipid nanoparticles (LNPs) serve as an effective, non-viral delivery system with a natural tendency to target the liver.
Challenges remain regarding the durability, immune response, and delivery of therapies beyond the liver.

Simplified

Inherited metabolic diseases (IMDs) are a diverse group of rare genetic disorders caused by enzymatic deficiencies that disrupt essential biochemical pathways. Current treatments remain largely supportive and fail to address the molecular root cause. Messenger RNA (mRNA)-based therapeutics, delivered by lipid nanoparticles (LNPs), have recently emerged as a powerful treatment strategy: mRNA enables transient and programmable protein expression, while LNPs provide an effective, non-viral vehicle with natural liver tropism. Initial phase I/II clinical trials and n = 1 cases in liver-dominant IMDs have shown encouraging results. Yet, given the rarity of each IMD and the small patient numbers in individual trials, definitive insights into efficacy and safety require integrating evidence across multiple disorders. In this review, we synthesize the emerging clinical trial evidence of mRNA-LNP therapies across IMDs, highlighting both enzyme replacement and genome editing strategies. We discuss the clinical promise and modularity of these approaches, alongside remaining challenges related to durability, immunogenicity, and extrahepatic delivery. The recent and anticipated evolving developments position mRNA-LNP therapeutics at the forefront of precision medicine, offering a flexible therapeutic platform with applications ranging from bridge therapy to long-term stabilization or potential one-time disease-modifying interventions, transforming the prospect of IMD management.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest None of the authors have financial disclosures nor personal relationships with other people or organization that could inappropriately influence or bias this manuscript.

PubMed

Using mRNA to Treat Inherited Metabolic Diseases

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief